FDA Approves Novartis’ New IL-17A-Blocking Psoriasis Drug Cosentyx
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.
Tag: Novartis
All
LatestSorry, No Posts Found
All
Latest
Why Patient Education Matters in Revision Rhinoplasty
Dr Anil Shah discusses how his book Nosecentric helps both patients and surgeons improve communication, set realistic goals, and reduce the risk of revision rhinoplasty.
